Last reviewed · How we verify
IgPro20 (low dose)
IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency.
IgPro20 is a subcutaneous immunoglobulin replacement therapy that provides passive immunity by delivering polyclonal human immunoglobulins to patients with primary immunodeficiency. Used for Primary immunodeficiency disorders requiring immunoglobulin replacement therapy.
At a glance
| Generic name | IgPro20 (low dose) |
|---|---|
| Also known as | Hizentra |
| Sponsor | CSL Behring |
| Drug class | Immunoglobulin replacement therapy |
| Target | Polyclonal human IgG |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
IgPro20 is a subcutaneous immunoglobulin (SCIg) product derived from pooled human plasma containing a broad spectrum of antibodies. The low-dose formulation is designed to maintain immunoglobulin levels in patients with primary immunodeficiency disorders, reducing the frequency and severity of infections. It works by providing exogenous antibodies that the patient's immune system cannot produce adequately.
Approved indications
- Primary immunodeficiency disorders requiring immunoglobulin replacement therapy
Common side effects
- Injection site reactions
- Headache
- Fatigue
- Fever
- Myalgia
Key clinical trials
- Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (PHASE3)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IgPro20 (low dose) CI brief — competitive landscape report
- IgPro20 (low dose) updates RSS · CI watch RSS
- CSL Behring portfolio CI